On this page
What each program costs in Colorado
The monthly price is all-in: the drug plus a membership when we have verified one. Compounded drugs are not FDA-approved.
| # | Program | Cheapest product | Plan | All in | Membership fee | Trustpilot | Checked | Seller site |
|---|---|---|---|---|---|---|---|---|
| 1 | Compounded Semaglutide | sale price | $39/mo | not verified | too few reviews | Visit | ||
| 2 | Compounded Semaglutide | 12-month plan, $588 up front | $49/mo | none | 3.9 (11,798 reviews) | Visit | ||
| 3 | Compounded Semaglutide | month to month | $59/mo | none | too few reviews | Visit | ||
| 4 | Compounded Semaglutide | 12-month plan, $828 up front | $69/mo | none | 4.6 (4,268 reviews) | Visit | ||
| 5 | Compounded Semaglutide | medication monthly, membership yearly | $75/mo | $199/yr, included | 4.8 (288 reviews) | Visit | ||
| 6 | Compounded Semaglutide | month to month | $79/mo | none | too few reviews | Visit | ||
| 7 | Compounded Semaglutide | month to month | $99/mo | none | 4.6 (5,235 reviews) | Visit | ||
| 8 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.3 (880 reviews) | Visit | ||
| 9 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.2 (218 reviews) | Visit | ||
| 10 | Compounded Semaglutide | 12-month plan, $1,260 up front | $105/mo | none | too few reviews | Visit | ||
| 11 | Compounded Semaglutide | 12-month plan, $1,698 up front | $141/mo | none | too few reviews | Visit | ||
| 12 | Semaglutide | month to month | $149/mo | none | too few reviews | Visit | ||
| 13 | Compounded Semaglutide | 12-month plan, $1,788 up front | $149/mo | none | 4.2 (777 reviews) | Visit | ||
| 14 | Microdosing Tirzepatide | 12-month plan, $2,028 up front | $169/mo | none | 4.0 (162 reviews) | Visit | ||
| 15 | Compounded Semaglutide | 2-month plan, $350 up front | $175/mo | none | 4.6 (1,084 reviews) | Visit | ||
| 16 | Compounded Oral Semaglutide Capsules | 6-month plan, $1,194 up front | $199/mo | none | too few reviews | Visit | ||
| 17 | Foundayo (brand orforglipron) | medication monthly, membership yearly | $208/mo | $59/mo, billed yearly, included | 4.6 (4,607 reviews) | Visit | ||
| 18 | Sublingual Semaglutide | month to month | $249/mo | none | 4.5 (17,622 reviews) | Visit | ||
| 19 | Compounded Semaglutide | month to month | $299/mo | none | too few reviews | Visit |
Does the State of Colorado employee health plan cover GLP-1s for weight loss?
Colorado restored state employee coverage of GLP-1s for weight loss on May 1, 2026, through its GLP-1 Benefit 360 Program. Members on the Cigna plan get Zepbound for weight loss unless another drug is medically necessary.
Colorado Division of Human Resources
The Department of Personnel and Administration says employee health plans cover GLP-1s for weight loss from May 1, 2026.
“Effective May 1, 2026, employee health plans will cover GLP-1s for weight loss.”
https://dhr.colorado.gov/state-employees/state-employee-benefits/medical-benefits · read Oct 29, 2026
Colorado Division of Human Resources
Cigna plan members get Zepbound for weight loss under the Benefit 360 Program.
“As part of the Benefit 360 Program, members on the Cigna plan will have access to the GLP-1 Zepbound for weight-loss indications, unless there is a medical necessity for another drug.”
https://dhr.colorado.gov/state-employees/state-employee-benefits/medical-benefits · read Oct 29, 2026
Does Colorado Medicaid (Health First Colorado) cover GLP-1s for weight loss?
Not covered for weight loss
Health First Colorado's preferred drug list says prior authorization for GLP-1 drugs prescribed solely for weight loss will not be approved, and it limits Wegovy to heart risk or a liver condition and Zepbound to sleep apnea. Read from state documents Nov 6, 2026.
What Colorado Medicaid (Health First Colorado)'s documents say about each drug for weight loss. Read Nov 6, 2026. Colorado Department of Health Care Policy and Financing.
WegovyNo
Prior authorization for established heart disease with overweight or obesity (BMI 25 or higher) and no type 2 diabetes, or for MASH with F2 to F3 fibrosis.
“Prior Authorization for GLP-1 analogues prescribed solely for weight loss will not be approved.”
Colorado Department of Health Care Policy and Financing · Effective Oct 13, 2026 · read Nov 6, 2026
“Wegovy (semaglutide) is being prescribed to decrease the risk of adverse cardiovascular events”
Colorado Department of Health Care Policy and Financing · Effective Oct 13, 2026 · read Nov 6, 2026
ZepboundNo
Prior authorization for adults with moderate to severe sleep apnea and BMI 30 or higher, after a CPAP trial or with a reason CPAP cannot be used.
“Prior Authorization for GLP-1 analogues prescribed solely for weight loss will not be approved.”
Colorado Department of Health Care Policy and Financing · Effective Oct 13, 2026 · read Nov 6, 2026
“Member has a documented diagnosis of moderate to severe obstructive sleep apnea (OSA)”
Colorado Department of Health Care Policy and Financing · Effective Oct 13, 2026 · read Nov 6, 2026
OzempicNo
Preferred for members with type 2 diabetes.
“Prior Authorization for GLP-1 analogues prescribed solely for weight loss will not be approved.”
Colorado Department of Health Care Policy and Financing · Effective Oct 13, 2026 · read Nov 6, 2026
“Preferred products may be approved for members with a diagnosis of type 2 diabetes.”
Colorado Department of Health Care Policy and Financing · Effective Oct 13, 2026 · read Nov 6, 2026
MounjaroNo
Preferred for members with type 2 diabetes.
“Prior Authorization for GLP-1 analogues prescribed solely for weight loss will not be approved.”
Colorado Department of Health Care Policy and Financing · Effective Oct 13, 2026 · read Nov 6, 2026
“Preferred products may be approved for members with a diagnosis of type 2 diabetes.”
Colorado Department of Health Care Policy and Financing · Effective Oct 13, 2026 · read Nov 6, 2026
This reports what the documents say. It is not medical or legal advice: your plan and your prescriber decide.
What changed, and when
- Nov 6, 2026 · This pageFirst read from Colorado Department of Health Care Policy and Financing documents. KFF's January 2026 map listed this program as not covered; the documents we read agree.
- Oct 1, 2026 · Policy changeMoved the Zepbound multidose KwikPen to preferred status, with PDL criteria that remain for sleep apnea.
“formulation will be changed to preferred status with criteria listed on the Preferred Drug List”
Colorado Department of Health Care Policy and Financing · Effective Oct 1, 2026 · read Nov 6, 2026
Weight loss
Not covered, read Nov 2026
Type 2 diabetes
Required in every state
Heart risk, sleep apnea
Required (Wegovy, Zepbound)
Prior authorization
Typical when covered
Wegovy, Zepbound, Saxenda, 2025
14,249 prescriptions
Ozempic and Mounjaro, 2025
43,699 prescriptions
Neighbours covering weight loss
1 of 7
Federal law lets each state decide whether Medicaid pays for drugs used for weight loss, while drugs approved for diabetes must be covered. A state document may not settle every plan; if your Colorado Medicaid coverage comes through a managed care plan, its formulary can differ, so ask the plan before you fill.
For comparison, a dated secondary source: KFF's January 2026 map listed Colorado Medicaid as "not covered" for GLP-1s for obesity under fee-for-service.
The BALANCE model
CMS’s BALANCE model lets state Medicaid programs add GLP-1s for weight management at a negotiated price. States could join on a rolling basis from May 1, 2026 through January 1, 2027, and the state application deadline was July 31, 2026. We could not find a published list of the states that joined, so this page does not say whether Colorado Medicaid did. Ask your plan. Either way your cost stays at Medicaid’s nominal copay, which BALANCE does not change.
The national picture, coupons and patient assistance: does Medicaid cover GLP-1s.
How many GLP-1s does Colorado Medicaid pay for?
123,001 GLP-1 prescriptions in 2025, 22nd of the 50 states and DC, with $126.2 million reimbursed before rebates. Counting the share other payers covered, $127.2 million.
Prescriptions, 2025
123,001
22nd of 51
Medicaid paid
$126.2M
22nd of 51, before rebates
Per prescription
$1,026
$1,051 nationally
Weight-loss brands
12%
17th highest share of 51
CMS State Drug Utilization Data 2025, updated Jul 13, 2026, fee-for-service and managed care, before rebates. Colorado is highlighted. CMS publishes this comparison as one year, not a trend.
Wegovy, Zepbound and Saxenda, the brands approved for weight management, were 12% of Colorado Medicaid's GLP-1 prescriptions in 2025 (14,249). Across the 13 states KFF lists as covering GLP-1s for obesity, the median share was 52%; across the other 38, 2.3%. Where weight loss is not covered, those brands are mostly filled for the uses Medicaid must cover, such as heart risk and sleep apnea. Trulicity was Colorado Medicaid's most filled GLP-1.
| Brand | Prescriptions | Share | Medicaid paid | Per Rx |
|---|---|---|---|---|
| Trulicity | 57,894 | 47% | $62.4 million | $1,077 |
| Mounjaro | 24,586 | 20% | $26.1 million | $1,061 |
| Ozempic | 19,113 | 16% | $19.0 million | $996 |
| Zepboundapproved for weight management | 7,443 | 6.1% | $6.8 million | $909 |
| Wegovyapproved for weight management | 6,806 | 5.5% | $8.1 million | $1,194 |
| Liraglutide (generic) | 4,233 | 3.4% | $1.7 million | $411 |
| Victoza | 1,826 | 1.5% | $820,218 | $449 |
| Rybelsus | 852 | 0.7% | $1.0 million | $1,188 |
| Bydureon | 158 | 0.1% | $164,885 | $1,044 |
| Byetta | 90 | 0.1% | $94,766 | $1,053 |
Source: CMS State Drug Utilization Data 2025, updated Jul 13, 2026, all four quarters, fee-for-service and managed care. Before rebates. CMS suppresses rows under 11 prescriptions, so small brands are undercounted slightly. Every state ranked: prescriptions and spending.
Which FDA-registered outsourcing facilities are in Colorado?
FDA's register of 503B outsourcing facilities, updated Nov 17, 2026, lists 4 in Colorado. The register does not say which, if any, supplies a program on this page.
- BSO LLC, Golden. Registered since Jan 24, 2024; last FDA inspection Nov 13, 2026.
- BSO LLC, Lakewood. Registered since Nov 24, 2015; last FDA inspection Jul 16, 2025.
- Denver Solutions, LLC, dba Leiters Health, Englewood. Registered since Mar 24, 2017; last FDA inspection Dec 11, 2025.
- STAQ Pharma, Inc., Denver. Registered since Feb 5, 2019; last FDA inspection Sep 8, 2026.
On Medicare in Colorado?
Medicare’s temporary GLP-1 Bridge works the same in every state: a $50 copay for a one-month supply of Wegovy, Foundayo or the Zepbound KwikPen, for people with Part D who meet its weight and health rules.
medicare.gov
“You’ll pay a $50 copayment to the pharmacy for a one-month supply (either 28 or 30 days, depending on drug).”
https://www.medicare.gov/coverage/weight-loss-drugs · read Nov 14, 2026
Colorado and the states around it
Medicaid’s weight-loss answer (the state’s own documents where we have read them, otherwise KFF, January 2026) and the partner programs that ship there, priced the same way as above.
1 of the 7 states next to Colorado covers GLP-1s for weight loss through Medicaid: Kansas. None has a lower cash floor than Colorado's $39.
| State | Medicaid, weight loss | Ship there | Cheapest that ships there |
|---|---|---|---|
| Colorado | Not covered | 19 | $39/mo |
| Arizona | Not covered in part | 19 | $39/moWellmedr |
| Kansas | Covered | 19 | $39/moWellmedr |
| Nebraska | Not covered | 19 | $39/moWellmedr |
| New Mexico | Not covered | 19 | $39/moWellmedr |
| Oklahoma | Not covered | 19 | $39/moWellmedr |
| Utah | Not confirmed | 19 | $39/moWellmedr |
| Wyoming | Not covered | 19 | $39/moWellmedr |






















